How to Choose the Best Treatment Strategy for Graves’ disease – Cooperation Between Doctor and Patient
DOI:
https://doi.org/10.12775/QS.2024.26.54944Keywords
Graves' disease, hyperthyroidism, treatment, thyroidectomy, radioiodine, antithyroid drugsAbstract
Graves' disease (GD) is an autoimmune thyroid disease characterized by hyperthyroidism, enlarged thyroid gland, and ophthalmopathy. It is the most common cause of hyperthyroidism, especially in middle-aged women. The pathological mechanism involves the production of antibodies against the TSH receptor (TRAbs), which leads to uncontrolled stimulation of the thyroid gland and excessive production of thyroid hormones.
This study examined optimal treatment strategies for Graves' disease, emphasizing the critical role of physician-patient collaboration. The paper discusses the clinical aspects of Graves' disease, focusing on the recurrent nature of the disease with periods of exacerbations and remissions. Additionally, attention is drawn to the commonly associated disease: orbitopathy, which may lead to permanent damage to the orbital tissues, eye movement disorders, deterioration of visual acuity, and even blindness.
The paper presents current therapeutic approaches, including pharmacotherapy, radioactive iodine treatment and surgical interventions. It emphasizes the importance of personalized treatment plans and the need for regular monitoring to minimize the risk of complications. This study emphasizes active patient involvement in treatment decisions to determine the most effective treatment strategy for Graves' disease, improving patient outcomes and quality of life.
References
Abraham, P., Avenell, A., Park, C. M., Watson, W. A., & Bevan, J. S. (2005). A systematic review of drug therapy for Graves' hyperthyroidism. European journal of endocrinology, 153(4), 489–498. https://doi.org/10.1530/eje.1.01993
Abraham-Nordling, M., Törring, O., Hamberger, B., Lundell, G., Tallstedt, L., Calissendorff, J., & Wallin, G. (2005). Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid : official journal of the American Thyroid Association, 15(11), 1279–1286. https://doi.org/10.1089/thy.2005.15.1279
Antonelli, A., Fallahi, P., Elia, G., Ragusa, F., Paparo, S. R., Ruffilli, I., Patrizio, A., Gonnella, D., Giusti, C., Virili, C., Centanni, M., Shoenfeld, Y., & Ferrari, S. M. (2020). Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best practice & research. Clinical endocrinology & metabolism, 34(1), 101388. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1016/j.beem.2020.101388
Azizi F. (2020). Long-Term Treatment of Hyperthyroidism with Antithyroid Drugs: 35 Years of Personal Clinical Experience. Thyroid : official journal of the American Thyroid Association, 30(10), 1451–1457. https://doi.org/10.1089/thy.2019.0814
Azizi, F., Abdi, H., Amouzegar, A., & Habibi Moeini, A. S. (2023). Long-term thionamide antithyroid treatment of Graves' disease. Best practice & research. Clinical endocrinology & metabolism, 37(2), 101631. https://doi.org/10.1016/j.beem.2022.101631
Bahn Chair, R. S., Burch, H. B., Cooper, D. S., Garber, J. R., Greenlee, M. C., Klein, I., Laurberg, P., McDougall, I. R., Montori, V. M., Rivkees, S. A., Ross, D. S., Sosa, J. A., Stan, M. N., American Thyroid Association, & American Association of Clinical Endocrinologists (2011). Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid : official journal of the American Thyroid Association, 21(6), 593–646. https://doi.org/10.1089/thy.2010.0417
Bartalena L. (2013). Diagnosis and management of Graves disease: a global overview. Nature reviews. Endocrinology, 9(12), 724–734. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1038/nrendo.2013.193
Bartalena, L., & Tanda, M. L. (2022). Current concepts regarding Graves' orbitopathy. Journal of internal medicine, 292(5), 692–716. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1111/joim.13524
Bobanga, I. D., & McHenry, C. R. (2019). Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy. Best practice & research. Clinical endocrinology & metabolism, 33(4), 101319. https://doi.org/10.1016/j.beem.2019.101319
Bolakale-Rufai, I. K., Abioro, I., Ngene, S. O., & Woldeamanuel, Y. (2023). Efficacy of methimazole before the administration of radioactive iodine in the management of Graves' disease: a systematic review and meta-analysis. Sao Paulo medical journal = Revista paulista de medicina, 141(5), e2022225. https://doi.org/10.1590/1516-3180.2022.0225.R1.19102022
Catargi, B., Leprat, F., Guyot, M., Valli, N., Ducassou, D., & Tabarin, A. (1999). Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. European journal of endocrinology, 141(2), 117–121. https://doi.org/10.1530/eje.0.1410117
Char D. H. (1991). The ophthalmopathy of Graves' disease. The Medical clinics of North America, 75(1), 97–119. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1016/s0025-7125(16)30474-6
El Kawkgi, O. M., Ross, D. S., & Stan, M. N. (2021). Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature. Clinical endocrinology, 95(1), 3–12. https://doi.org/10.1111/cen.14374
European Group of Graves' Orbitopathy, Perros, P., Baldeschi, L., Boboridis, K., Dickinson, A. J., Hullo, A., Kahaly, G. J., Kendall-Taylor, P., Krassas, G. E., Lane, C. M., Lazarus, J. H., Marcocci, C., Marino, M., Mourits, M. P., Nardi, M., Orgiazzi, J., Pinchera, A., Pitz, S., Prummel, M. F., & Wiersinga, W. M. (2006). A questionnaire survey on the management of Graves' orbitopathy in Europe. European journal of endocrinology, 155(2), 207–211. https://doi.org/10.1530/eje.1.02201
Feroci, F., Rettori, M., Borrelli, A., Coppola, A., Castagnoli, A., Perigli, G., Cianchi, F., & Scatizzi, M. (2014). A systematic review and meta-analysis of total thyroidectomy versus bilateral subtotal thyroidectomy for Graves' disease. Surgery, 155(3), 529–540. https://doi.org/10.1016/j.surg.2013.10.017
Franklyn J. A. (1994). The management of hyperthyroidism. The New England journal of medicine, 330(24), 1731–1738. https://doi.org/10.1056/NEJM199406163302407
Genovese, B. M., Noureldine, S. I., Gleeson, E. M., Tufano, R. P., & Kandil, E. (2013). What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Annals of surgical oncology, 20(2), 660–667. https://doi.org/10.1245/s10434-012-2606-x
Hegedüs L. (2009). Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinology and metabolism clinics of North America, 38(2), 355–ix. https://doi.org/10.1016/j.ecl.2009.01.009
Jarløv, A. E., Hegedüs, L., Kristensen, L. O., Nygaard, B., & Hansen, J. M. (1995). Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?. Clinical endocrinology, 43(3), 325–329. https://doi.org/10.1111/j.1365-2265.1995.tb02039.x
Jin, M., Jang, A., Kim, C. A., Kim, T. Y., Kim, W. B., Shong, Y. K., Jeon, M. J., & Kim, W. G. (2023). Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort. European thyroid journal, 12(2), e220226. https://doi.org/10.1530/ETJ-22-0226
Liu, Z. W., Masterson, L., Fish, B., Jani, P., & Chatterjee, K. (2015). Thyroid surgery for Graves' disease and Graves' ophthalmopathy. The Cochrane database of systematic reviews, 2015(11), CD010576. https://doi.org/10.1002/14651858.CD010576.pub2
Ma, C., Xie, J., Wang, H., Li, J., & Chen, S. (2016). Radioiodine therapy versus antithyroid medications for Graves' disease. The Cochrane database of systematic reviews, 2(2), CD010094. https://doi.org/10.1002/14651858.CD010094.pub2
McDougall I. R. (1991). Graves' disease. Current concepts. The Medical clinics of North America, 75(1), 79–95. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1016/s0025-7125(16)30473-4
McIver, B., & Morris, J. C. (1998). The pathogenesis of Graves' disease. Endocrinology and metabolism clinics of North America, 27(1), 73–89. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1016/s0889-8529(05)70299-1
Pattou, F., Combemale, F., Fabre, S., Carnaille, B., Decoulx, M., Wemeau, J. L., Racadot, A., & Proye, C. (1998). Hypocalcemia following defiry: incidence and prediction of outcome. World journal of surgery, 22(7), 718–724. https://doi.org/10.1007/s002689900459
Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., Rivkees, S. A., Samuels, M., Sosa, J. A., Stan, M. N., & Walter, M. A. (2016). 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid : official journal of the American Thyroid Association, 26(10), 1343–1421. https://doi.org/10.1089/thy.2016.0229
Rotondi, M., Virili, C., Pinto, S., Coperchini, F., Croce, L., Brusca, N., Centanni, M., & Chiovato, L. (2020). The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases. Journal of endocrinological investigation, 43(2), 157–162. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1007/s40618-019-01094-7
Santos, R. B., Romaldini, J. H., & Ward, L. S. (2004). Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid : official journal of the American Thyroid Association, 14(7), 525–530. https://doi.org/10.1089/1050725041517093
Shi, H., Sheng, R., Hu, Y., Liu, X., Jiang, L., Wang, Z., & Cui, D. (2020). Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. Clinical therapeutics, 42(4), 662–675.e4. https://doi.org/10.1016/j.clinthera.2020.01.022
Sjölin, G., Holmberg, M., Törring, O., Byström, K., Khamisi, S., de Laval, D., Abraham-Nordling, M., Calissendorff, J., Lantz, M., Hallengren, B., Filipsson Nyström, H., & Wallin, G. (2019). The Long-Term Outcome of Treatment for Graves' Hyperthyroidism. Thyroid : official journal of the American Thyroid Association, 29(11), 1545–1557. https://doi.org/10.1089/thy.2019.0085
Sosa, J. A., Bowman, H. M., Tielsch, J. M., Powe, N. R., Gordon, T. A., & Udelsman, R. (1998). The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Annals of surgery, 228(3), 320–330. https://doi.org/10.1097/00000658-199809000-00005
Sridama, V., McCormick, M., Kaplan, E. L., Fauchet, R., & DeGroot, L. J. (1984). Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. The New England journal of medicine, 311(7), 426–432. https://doi.org/10.1056/NEJM198408163110702
Streetman, D. D., & Khanderia, U. (2003). Diagnosis and treatment of Graves disease. The Annals of pharmacotherapy, 37(7-8), 1100–1109. https://doi-1org-100001adi1210.han3.wum.edu.pl/10.1345/aph.1C299
Subekti, I., & Pramono, L. A. (2018). Current Diagnosis and Management of Graves' Disease. Acta medica Indonesiana, 50(2), 177–182.
Sundaresh, V., Brito, J. P., Wang, Z., Prokop, L. J., Stan, M. N., Murad, M. H., & Bahn, R. S. (2013). Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. The Journal of clinical endocrinology and metabolism, 98(9), 3671–3677. https://doi.org/10.1210/jc.2013-1954
Törring, O., Watt, T., Sjölin, G., Byström, K., Abraham-Nordling, M., Calissendorff, J., Cramon, P. K., Filipsson Nyström, H., Hallengren, B., Holmberg, M., Khamisi, S., Lantz, M., & Wallin, G. (2019). Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey. Thyroid : official journal of the American Thyroid Association, 29(3), 322–331. https://doi.org/10.1089/thy.2018.0315
Welch, K. C., & McHenry, C. R. (2011). Total thyroidectomy: is morbidity higher for Graves' disease than nontoxic goiter?. The Journal of surgical research, 170(1), 96–99. https://doi.org/10.1016/j.jss.2011.03.054
Brix, T. H., Kyvik, K. O., Christensen, K., & Hegedüs, L. (2001). Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. The Journal of clinical endocrinology and metabolism, 86(2), 930–934. https://doi.org/10.1210/jcem.86.2.7242
Brand, O. J., & Gough, S. C. (2010). Genetics of thyroid autoimmunity and the role of the TSHR. Molecular and cellular endocrinology, 322(1-2), 135–143. https://doi.org/10.1016/j.mce.2010.01.013
Prabhakar, B. S., Bahn, R. S., & Smith, T. J. (2003). Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocrine reviews, 24(6), 802–835. https://doi.org/10.1210/er.2002-0020
Vishnu Sundaresh, Juan P. Brito, Zhen Wang, Larry J. Prokop, Marius N. Stan, Mohammad H. Murad, Rebecca S. Bahn, Comparative Effectiveness of Therapies for Graves' Hyperthyroidism: A Systematic Review and Network Meta-Analysis, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 9, 1 September 2013, Pages 3671–3677, https://doi.org/10.1210/jc.2013-1954
Brito, J. P., Payne, S., Singh Ospina, N., Rodriguez-Gutierrez, R., Maraka, S., Sangaralingham, L. R., Iñiguez-Ariza, N. M., Montori, V. M., & Stan, M. N. (2020). Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves' Disease: A Nationwide Population-Based Study. Thyroid : official journal of the American Thyroid Association, 30(3), 357–364. https://doi.org/10.1089/thy.2019.0132
Cooper D. S. (2005). Antithyroid drugs. The New England journal of medicine, 352(9), 905–917. https://doi.org/10.1056/NEJMra042972
Nakamura, H., Noh, J. Y., Itoh, K., Fukata, S., Miyauchi, A., & Hamada, N. (2007). Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. The Journal of clinical endocrinology and metabolism, 92(6), 2157–2162. https://doi.org/10.1210/jc.2006-2135
Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S. (2010). Antithyroid drug regimen for treating Graves' hyperthyroidism. The Cochrane database of systematic reviews, 2010(1), CD003420. https://doi.org/10.1002/14651858.CD003420.pub4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Paula Kula, Mateusz Haber, Adrianna Czachor, Natalia Kucy, Alicja Kotula, Olga Grelewicz, Elwira Servaas, Adam Juśkiewicz, Robert Siemiątkowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 172
Number of citations: 0
